Johnson & Johnson (JNJ) Reports CARVYKTI achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. GNK
6. HTFL
7. SNDK
8. DVLT
9. ADYYF
10. WDAY

Go back to Johnson & Johnson (JNJ) Reports CARVYKTI achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study

CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study

July 2, 2024 7:30 AM EDT

CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapy

RARITAN, N.J., July 2, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today positive results from a prespecified second interim analysis of the Phase 3 CARTITUDE-4 study evaluating CARVYKTI®... More